论文部分内容阅读
非对称二甲基精氨酸(ADMA)是天然的L-精氨酸同系物,广泛存在于人体的血液和组织中。作为一氧化氮合成酶(NOS)抑制剂,其可通过降低NO的生物利用度而诱导心血管疾病的发生发展。目前临床研究已发现,ADMA除与慢性肾脏病(CKD)中的心血管并发症密切相关外,还可以作为CKD进展的预测指标。本文将从ADMA的合成、代谢、病生理机制及治疗入手,介绍ADMA对促进CKD进展等相关领域的最新发现。
Asymmetric dimethylarginine (ADMA) is a natural homolog of L-arginine, widely found in the body’s blood and tissues. As a nitric oxide synthase (NOS) inhibitor, it can induce the development of cardiovascular diseases by reducing the bioavailability of NO. Current clinical studies have found that ADMA, in addition to cardiovascular disease in chronic kidney disease (CKD) are closely related, but also can be used as a predictor of CKD progress. This article will start from ADMA synthesis, metabolism, disease and physiological mechanism and treatment, introduces ADMA on the promotion of CKD progress and other related areas of the latest findings.